Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.

Hastak K, Alli E, Ford JM.

Cancer Res. 2010 Oct 15;70(20):7970-80. doi: 10.1158/0008-5472.CAN-09-4521. Epub 2010 Aug 26.

2.

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Janku F, Stewart DJ, Kurzrock R.

Nat Rev Clin Oncol. 2010 Jul;7(7):401-14. doi: 10.1038/nrclinonc.2010.64. Epub 2010 Jun 15. Review. Erratum in: Nat Rev Clin Oncol. 2011 Jul;8(7):384.

PMID:
20551945
3.

Long-term survival following metachronous intratumoral hemorrhage in an HIV-infected patient with lung cancer.

Okuma Y, Hosomi Y, Takagi Y, Miyamoto S, Shimokawa T, Iguchi M, Okamura T, Saito K, Shibuya M.

Int J Clin Oncol. 2010 Oct;15(5):515-8. doi: 10.1007/s10147-010-0072-7. Epub 2010 May 11.

PMID:
20455086
4.

Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer.

Makinson A, Pujol JL, Le Moing V, Peyriere H, Reynes J.

J Thorac Oncol. 2010 Apr;5(4):562-71. doi: 10.1097/JTO.0b013e3181d3ccf2. Review.

5.

Survivin: a new target for anti-cancer therapy.

Ryan BM, O'Donovan N, Duffy MJ.

Cancer Treat Rev. 2009 Nov;35(7):553-62. doi: 10.1016/j.ctrv.2009.05.003. Epub 2009 Jun 25. Review.

PMID:
19559538
6.

Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.

Zhang YW, Jones TL, Martin SE, Caplen NJ, Pommier Y.

J Biol Chem. 2009 Jul 3;284(27):18085-95. doi: 10.1074/jbc.M109.003020. Epub 2009 May 5.

7.

Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.

Kumar S, Bryant CS, Chamala S, Qazi A, Seward S, Pal J, Steffes CP, Weaver DW, Morris R, Malone JM, Shammas MA, Prasad M, Batchu RB.

Mol Cancer. 2009 Apr 22;8:26. doi: 10.1186/1476-4598-8-26.

8.

Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links.

Zhu G, Lippard SJ.

Biochemistry. 2009 Jun 9;48(22):4916-25. doi: 10.1021/bi900389b.

9.

Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells.

Jiang G, Ren B, Xu L, Song S, Zhu C, Ye F.

Anticancer Res. 2009 Jan;29(1):223-8.

10.

Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA.

Guggenheim ER, Xu D, Zhang CX, Chang PV, Lippard SJ.

Chembiochem. 2009 Jan 5;10(1):141-57. doi: 10.1002/cbic.200800471.

11.

ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.

Ewald B, Sampath D, Plunkett W.

Cancer Res. 2008 Oct 1;68(19):7947-55. doi: 10.1158/0008-5472.CAN-08-0971.

12.

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.

Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG.

J Clin Oncol. 2008 Jun 1;26(16):2699-706. doi: 10.1200/JCO.2007.15.2355.

PMID:
18509182
13.

The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures.

Fan J, Wang L, Jiang GN, He WX, Ding JA.

Lung Cancer. 2008 Jul;61(1):91-6. doi: 10.1016/j.lungcan.2007.11.011. Epub 2008 Jan 14.

PMID:
18192073
14.

Survivin, cancer networks and pathway-directed drug discovery.

Altieri DC.

Nat Rev Cancer. 2008 Jan;8(1):61-70. Review.

PMID:
18075512
15.

Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner.

Moser J, Kool H, Giakzidis I, Caldecott K, Mullenders LH, Fousteri MI.

Mol Cell. 2007 Jul 20;27(2):311-23.

16.

Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis.

Ulukus EC, Kargi HA, Sis B, Lebe B, Oztop I, Akkoclu A, Onen A, Sanli A.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):31-7.

PMID:
17536304
17.

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.

Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY.

Clin Cancer Res. 2007 May 1;13(9):2795-803.

18.

Inhibition of angiogenesis by the antifungal drug itraconazole.

Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr, Liu JO.

ACS Chem Biol. 2007 Apr 24;2(4):263-70.

PMID:
17432820
19.

SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.

Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM.

Am J Pathol. 2007 Jan;170(1):366-76.

20.

Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells.

Song H, Xin XY, Xiao F, Wang DT, Yue QH, Han X.

Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):83-9. Epub 2006 Nov 13.

PMID:
17098350

Supplemental Content

Support Center